Download the full description of this project: ESR7: Understanding PDE binding kinetics
This project will investigate of binding kinetic while growing hit fragments, building on interesting data that has already been generated for Trypanosoma brucei Tbr-PDE ligands. The project will combine design, synthesis and molecular dynamics studies to unravel the molecular features of structure-kinetics relationships.
1. Use SPR biosensors to measure the differences in binding kinetics of ligands for human hPDE4 and parasite TbrPDE proteins.
2. Perform Random Acceleration Molecular Dynamics (RAMD) studies to determine ligand access and egress mechanisms and factors determining the kinetics of ligand binding to PDEs.
3. Guide fragment hit growing to develop optimised compounds with well-‐defined kinetic selectivity profiles.
Trypanosoma brucei (Tbr) is the causative parasite of human African trypanosomiasis (HAT), also known asAfrican sleeping sickness, a disease that has been grossly neglected as it is only a problem in the poorest areas of Africa. Tbr-‐PDE enzymes are validated drug targets to treat this illness. These Fragnet studies will lead to a better understanding of kinetic binding properties of Tbr-‐ PDE ligands. This molecular understanding can be used to achieve kinetic selectivity and thereby create safe and efficient drugs for this neglected disease.
AApplicants must have a background in molecular modelling (including molecular dynamics studies). Experience with organic synthesis or SPR biosensor instruments would be an advantage. The project can be fine-‐tuned according to the background and interests of the successful candidate.
1. Jansen et al. J. Med. Chem. 2013, 56, 2087-2096.
2. Orrling et al. Discov Today. 2012, 55, 8745-8756.
- ESR1: 3D Fragments with small aliphatic rings - David Hamilton
- ESR2: Novel 3D fragments - Hanna Francesca Klein
- ESR3: Warhead Library of Covalent Fragment Binders - Aaron Keeley
- ESR4: Development of FBLD techniques for Intrinsically Disordered Proteins - Darius Vagrys
- ESR5: Biophysics Based FBLD - Sébastien Keiffer
- ESR6: FBLD experimental methods - Edward Fitzgerald
- ESR8: Virtual Screening of Fragment Libraries of Covalent Binders - Andrea Scarpino
- ESR9: Fragment evolution platform - chemical navigation - Moira Rachman
- ESR10: Fragment evolution platform – molecular simulations - Maciej Majewski
- ESR11: Fragment-based approaches to identify novel PPI inhibitors - Lorena Zara
- ESR12: Covalent fragments to activate industrial enzymes - Eleni Makraki
- ESR13: Fragment-based assessment of new antibiotic target - Bas Lamoree
- ESR14: Targeting allosteric pockets with FBLD - Lena Münzker
- ESR15: Science, Business & Innovation in the pharmaceutical sciences - Angelo Kenneth Romasanta